Literature DB >> 33472093

Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK.

Julian W Tang1, Oliver T R Toovey2, Kirsty N Harvey2, David D S Hui3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33472093      PMCID: PMC7813514          DOI: 10.1016/j.jinf.2021.01.007

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
The current surge of COVID-19 cases across the UK is now thought to be mostly driven by a new, highly transmissible SARS-CoV-2 variant (B.1.1.7/ VUI-202,012/01), but another highly transmissible SARS-CoV-2 variant (B.1.351/501Y.V2) from South Africa has already been detected in the UK population [https://cov-lineages.org/global_report.html]. This South African 501Y.V2 variant is characterised by three mutations in the SARS-CoV-2 spike (S) protein: K417N (a lysine to asparagine substitution at amino acid position 417 in the S protein), E484K (a glutamic acid to lysine substitution at amino acid position 484 in the S protein) and N501Y (an asparagine to tyrosine substitution at amino acid position 501 in the S protein). This last mutation is also present in the UK VUI-202,012/01 variant. This 501Y.V2 variant likely emerged from the first wave of the South African COVID-19 epidemic in the hardest hit Nelson Mandela Bay metropolitan area of the Eastern Cape Province in early October 2020, then spread quickly to become the predominant virus lineage in the Eastern and Western Cape Provinces by the end of November 2020. This virus variant soon spread to neighbouring Botswana in December 2020, as well as several other countries worldwide including England, Scotland, France, Sweden, Switzerland, South Korea during December 2020, and Australia in January 2021 (Fig. 1 ). This phylogenetic reconstruction of the whole genome viral sequences suggests that there may have been up to 8–9 independent introductions of the 501Y.V2 variant into England and 2 into Scotland, though the details of the epidemiological linkage between these cases is unknown.
Fig. 1

A maximum likelihood tree of South African variant B.1.351/501Y.V2 (downloaded 7 January 2021, from GISAID: https://www.gisaid.org/). Sequences were aligned using MAFFT: https://mafft.cbrc.jp/alignment/software/ and manually edited using BioEdit v7.2.5. Phylogenetic tree construction was performed using FastTree v2.1.11 and displayed using FigTree v1.4.4. We gratefully acknowledge and thank all the teams and laboratories that have deposited these sequences into GISAID to make this analysis possible. Red and blue brackets denote 501Y.V2 viruses detected in England or Scotland, respectively, together with any closely related sequences from elsewhere. The larger, bold red bracket indicates a larger cluster of possibly linked viruses that are closely related to viruses from France. Note that this tree is intended to be illustrative and not comprehensive.

A maximum likelihood tree of South African variant B.1.351/501Y.V2 (downloaded 7 January 2021, from GISAID: https://www.gisaid.org/). Sequences were aligned using MAFFT: https://mafft.cbrc.jp/alignment/software/ and manually edited using BioEdit v7.2.5. Phylogenetic tree construction was performed using FastTree v2.1.11 and displayed using FigTree v1.4.4. We gratefully acknowledge and thank all the teams and laboratories that have deposited these sequences into GISAID to make this analysis possible. Red and blue brackets denote 501Y.V2 viruses detected in England or Scotland, respectively, together with any closely related sequences from elsewhere. The larger, bold red bracket indicates a larger cluster of possibly linked viruses that are closely related to viruses from France. Note that this tree is intended to be illustrative and not comprehensive. One hypothesis about the origins of this variant is through intra-host viral evolution due to prolonged infection in an immunocompromised host. Indeed, in this case report, the appearance of the E484K and N501Y mutations were described after 75 and 128 days of infection, respectively. However, this cannot be the only mechanism, as multiple other mutations are present that would require contributions from other viral lineages. Additional mutations in other viral genes may also be secondary mutations that may have arisen as ‘compensatory’ mutations to reduce any fitness penalty resulting from these S protein changes (K417N, E484K, N501Y). Currently, the 501Y.V2 variant is considered to be a more highly transmissible strain due to the rapidity with which it became predominant in this South African population over just a few weeks. There are also some real concerns that the mutations in the S protein (K417N, E484K, N501Y) may result in conformation changes that may impact on the effectiveness of COVID-19 vaccines developed based on earlier SARS-CoV-2 strains. However a recent small study examining the impact of the N501Y mutation on the recently licensed Pfizer-BioNTech vaccine did not show any loss of antibody neutralisation efficacy, though similar further studies examining the impact of this N501Y and the other mutations (K417N, E484K) on the various other COVID-19 vaccines are also required. There appears to be no indication of increased severity of illness, as yet, though research is ongoing in both the UK and South Africa to further characterise the phenotype of this South African 501Y.V2 variant. Despite the presence of these two more transmissible SARS-CoV-2 variants, the public health messaging remains the same to reduce the spread of these viruses: to maintain social distancing, including masking in crowded indoor areas, and limit the number of contacts that we have each day.

Declaration of Competing Interest

None.
  2 in total

1.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.

Authors:  Bina Choi; Manish C Choudhary; James Regan; Jeffrey A Sparks; Robert F Padera; Xueting Qiu; Isaac H Solomon; Hsiao-Hsuan Kuo; Julie Boucau; Kathryn Bowman; U Das Adhikari; Marisa L Winkler; Alisa A Mueller; Tiffany Y-T Hsu; Michaël Desjardins; Lindsey R Baden; Brian T Chan; Bruce D Walker; Mathias Lichterfeld; Manfred Brigl; Douglas S Kwon; Sanjat Kanjilal; Eugene T Richardson; A Helena Jonsson; Galit Alter; Amy K Barczak; William P Hanage; Xu G Yu; Gaurav D Gaiha; Michael S Seaman; Manuela Cernadas; Jonathan Z Li
Journal:  N Engl J Med       Date:  2020-11-11       Impact factor: 91.245

2.  Emergence of a new SARS-CoV-2 variant in the UK.

Authors:  Julian W Tang; Paul A Tambyah; David Sc Hui
Journal:  J Infect       Date:  2020-12-28       Impact factor: 6.072

  2 in total
  62 in total

1.  How will emerging SARS-CoV-2 variants impact herd immunity?

Authors:  Giuseppe Lippi; Brandon M Henry
Journal:  Ann Transl Med       Date:  2021-04

2.  Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies.

Authors:  Garima Kumar; Sarah Sterrett; Lucinda Hall; Edlue Tabengwa; Kazuhito Honjo; Michael Larimer; Randall S Davis; Paul A Goepfert; Benjamin M Larimer
Journal:  Protein Eng Des Sel       Date:  2022-02-17       Impact factor: 1.650

Review 3.  COVID-19: breaking down a global health crisis.

Authors:  Saad I Mallah; Omar K Ghorab; Sabrina Al-Salmi; Omar S Abdellatif; Tharmegan Tharmaratnam; Mina Amin Iskandar; Jessica Atef Nassef Sefen; Pardeep Sidhu; Bassam Atallah; Rania El-Lababidi; Manaf Al-Qahtani
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-05-18       Impact factor: 3.944

4.  Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?

Authors:  Gaia Spinetti; Elisa Avolio; Paolo Madeddu
Journal:  Regen Med       Date:  2021-05-14       Impact factor: 3.806

Review 5.  An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.

Authors:  Cielo García-Montero; Oscar Fraile-Martínez; Coral Bravo; Diego Torres-Carranza; Lara Sanchez-Trujillo; Ana M Gómez-Lahoz; Luis G Guijarro; Natalio García-Honduvilla; Angel Asúnsolo; Julia Bujan; Jorge Monserrat; Encarnación Serrano; Melchor Álvarez-Mon; Juan A De León-Luis; Miguel A Álvarez-Mon; Miguel A Ortega
Journal:  Vaccines (Basel)       Date:  2021-04-27

6.  From Alpha to Zeta: Identifying Variants and Subtypes of SARS-CoV-2 Via Clustering.

Authors:  Andrew Melnyk; Fatemeh Mohebbi; Sergey Knyazev; Bikram Sahoo; Roya Hosseini; Pavel Skums; Alex Zelikovsky; Murray Patterson
Journal:  J Comput Biol       Date:  2021-10-25       Impact factor: 1.479

7.  The Immunopathobiology of SARS-CoV-2 Infection.

Authors:  Milankumar Patel; Farah Shahjin; Jacob D Cohen; Mahmudul Hasan; Jatin Machhi; Heerak Chugh; Snigdha Singh; Srijanee Das; Tanmay A Kulkarni; Jonathan Herskovitz; Douglas D Meigs; Ramesh Chandra; Kenneth S Hettie; R Lee Mosley; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  FEMS Microbiol Rev       Date:  2021-11-23       Impact factor: 16.408

Review 8.  Understanding COVID-19: are children the key?

Authors:  Suz Warner; Alex Richter; Zania Stamataki; Deirdre Kelly
Journal:  BMJ Paediatr Open       Date:  2021-05-19

9.  The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-γ production in vitro.

Authors:  Jinglu Lyu; Lirong Bao; Xin Shen; Caixia Yan; Cheng Zhang; Wei Wei; Yutao Yang; Jia Li; Jiajia Dong; Liying Xiao; Xuedong Zhou; Yan Li
Journal:  Int Immunopharmacol       Date:  2021-05-19       Impact factor: 5.714

Review 10.  Evolution, Ecology, and Zoonotic Transmission of Betacoronaviruses: A Review.

Authors:  Herbert F Jelinek; Mira Mousa; Eman Alefishat; Wael Osman; Ian Spence; Dengpan Bu; Samuel F Feng; Jason Byrd; Paola A Magni; Shafi Sahibzada; Guan K Tay; Habiba S Alsafar
Journal:  Front Vet Sci       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.